Amryt Pharma has signed an exclusive distribution agreement covering central and eastern Europe with GryNumber Health which further expands the route to market for Lojuxta (lomitapide).
Amryt said the agreement covers the distribution of Lojuxta across Austria, Croatia, Czech Republic, Estonia, Finland, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.
Lojuxta is a treatment for the rare, life-threatening, genetic cholesterol disorder Homozygous Familial Hypercholesterolemia .
Amryt estimates that there are approximately 100 patients with HoFH in these countries, with requests for access to Lojuxta made by clinicians throughout the region. Amryt signed distribution contracts covering Saudi Arabia and Switzerland recently as it continues to develop sales of Lojuxta, having acquired exclusive marketing rights to the drug across certain territories in December 2016.
At 9:31am: (LON:AMYT) Amryt Pharma share price was +0.05p at 20.05p